Company profile
Poniard Pharmaceuticals, Inc.
OTC: PARD · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 40
v0.1 · 5/100 weight · pillars only
↑ listing tenure, balance-sheet leverage · ↓ market scale, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$30.1M
Employees
7
as of 2026-08-31
Market cap
$150
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02010
Net income-$30.1M-$30.1M2010
Operating income-$28.0M-$28.0M2010
Total assets$11.6M$11.6M2010
Liabilities$3.2M$3.2M2010
Equity$8.5M$8.5M2010
Revenue trend
FY2003 – FY2010 · USD
FY03
FY04
FY05
FY06
FY07
FY08
FY09
FY10
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Poniard Pharmaceuticals, Inc.’s revenue?
Poniard Pharmaceuticals, Inc. booked $0 in FY2010 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Lexington Biosciences, Inc.——Thoughtful Brands Inc.——Greenwind Holdings Inc.——NexImmune, Inc.——ContraFect Corp.——Heart Tronics, Inc.——Neighbors
King →Key facts
CEORobert F. Caspari
SectorHealthcare
IndustryBiotechnology
HeadquartersSeattle, WA
ExchangeOTC: PARD
Employees7
IPO date1988-08-11
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.